Next Phase Newsletter

A diversified, global, alternative asset manager has invested equally in the private and public markets. Within the private markets, the firm seeks to invest across the entire private healthcare company lifecycle, from seed to cross-over. Initial check sizes can range from $5 – 50m and will largely depend on the stage of the company. With seed stage companies, the firm can invest $1-5m. In general, the firm ascribes to the approach of doubling the size of their prior round investment in each subsequent round (from Seed -> Series A -> Series B -> Series C -> IPO), subject to milestone achievement. The firm is currently focused on USA and Western European opportunities.

The firm’s primary investment focus is disruptive therapeutics-focused companies. The firm is most interested in genetic medicines (DNA, RNA, protein-targeted therapies including gene therapy, gene editing, oligonucleotides, and small molecule approaches), precision/targeted oncology (DNA damage repair/synthetic lethality, driver/resistance mechanisms), differentiated immunotherapies (gamma-delta T-cell-targeted, bispecific T-cell engagers, new efforts at drugging difficult checkpoints/targets), CNS disorders and autoimmune disorders (new targets of interest). The firm may consider therapeutics indications outside of CNS, oncology, and autoimmune disease on a much more selective basis. In terms of stage of development, the firm is open to pre-clinical opportunities from the lead optimization phase and beyond (discovery phase will be considered too early). The firm may consider opportunities outside of therapeutics including medical devices, diagnostics, tools and digital health, but will be much more selective.

The firm has no particular company or management team requirements. The firm is willing to lead rounds but can act as a follow-on – the firm may seek board representation when acting as the lead investor. The firm seeks to hold shares of their private company investments long after their successful IPO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences Venture Capital firm based in USA and Canada typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with offices in USA and Europe typically makes equity investments into early-stage life science companies. The typical investment size ranges from €5-10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office located in Canada looks to invest in clinical stage medical devices and diagnostics technologies as well as digital health companies. The firm looks to invest in companies with large market opportunities. The firm prefers to invest in Canadian companies, but will consider companies outside of Canada if they wish to expand to the Canadian market. The firm prefers to co-invest alongside other investors, and will invest $100,000-$250,000 in the initial investment, potentially contributing to additional rounds of funding.

The firm is looking for device companies, either in the medical device or diagnostic space. The firm will also consider digital health companies, focusing on mobile applications. For devices and diagnostics, the firm prefers 510k devices, but will consider PMA devices as well. These devices should be in the clinical development phase. The firm is indication agnostic, but does look for there to be a large market potential.

The firm looks for companies with strong management teams with good team dynamics, although previous entrepreneurial experience is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2019, a newly established venture capital firm is headquartered in Tokyo, Japan. The firm is a carve-out of the Private Equity investment arm of a leading diversified financial institution, which has invested in over 76 companies over 2004-2018 (out of which 24 succeeded in IPO). The firm manages the fund that is dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in January 2018, the firm is a venture capital based in Shenzhen, China. The firm focused on big data and IOT-related healthcare investment opportunities. The firm is currently managing a 500 million RMB fund and is actively looking to invest 10-20 new deals in the following 12 months. The firm invests mostly in Medical Devices, Diagnostics, and Digital Health companies but will also consider drugs in applicable cases. The firm is currently looking for new opportunities globally, however, following China’s latest healthcare development strategy would be an important consideration although not required for their investment opportunities. The size of investment can vary from 10 – 30 million depending on the deal.

The firm is interested in medtech, diagnostics, and digital health companies that are seeking for early financing round. The firm’s sweet spot is to invest in angel to pre-A round. The firm will not invest in B round or later rounds. The firm is especially interested in technology with a big-data component and has invested in molecular diagnostics and digital health companies previously. The firm is opportunistic in terms of subsectors and indications.

The firm is seeking to invest in management teams with strong research or industry background. Management teams that graduated from the world’s top universities or has worked for big pharma is a plus. The firm also prefers serial entrepreneurs with successful track records.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A newly established venture capital firm based in the USA just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.